Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

GP44729

99 years and younger
All genders
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, humanized antiinterleukin-6 (IL-6) receptor monoclonal antibody, in participants with moderate-to-severe thyroid eye disease (TED).
Learn More

UPCC 27423 V-RULES: Vyxeos Real-world US Long-term Effectiveness and Safety Study

99 years and younger
All genders
This is a retrospective, non-interventional, multi-center, single-arm, observational study of patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who have been treated with Vyxeos in real world clinical practice and managed as per the healthcare providers discretion. The study will collect pseudonymized patient …
Learn More

IMPAHCT:

99 years and younger
All genders
This phase 2b/3 study will use AV-101 dry powder for oral inhalation in patients with PAH. Procedures include PEs, vital signs, safety labs, right heart caths, echocardiograms, QOL questionnaires, 6MWTs, lung function tests, and PK labs.
Learn More

RGX-314-3101

99 years and younger
All genders
This phase 3, partially masked, randomized, multicenter study will include 2 periods: an Active Run-in Period (ie, Screening) and an Assessment Period. Participants who receive RGX-314 will be provided the opportunity to enroll into a long-term follow-up (LTFU) study (RGX-314-5101) after completion of or early discontinuation from this current study …
Learn More

ARISE Pivotal

99 years and younger
All genders
Assess the safety and effectiveness of the ASG (Ascending Stent Graft) device in the treatment of lesions involving the ascending aorta and aortic arch. This study involves patients considered to be at high-risk for open surgical repair who present with the following pathologies of the ascending aorta and aortic arch …
Learn More

UPCC 23222: A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas

99 years and younger
All genders
This is a multi-center, open-label, single arm Phase 1b/2a study of gemcitabine and nab-paclitaxel in combination with VS-6766 and defactinib in patients with previously untreated metastatic PDAC. We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 16923 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

99 years and younger
All genders
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors.
Learn More

Target-LD

99 years and younger
All genders
An Observational Study of Patients with Chronic Liver Disease
Learn More

Abbvie M21-446

99 years and younger
All genders
Study M21-446 is a Phase 2a, multicenter, open label proof of concept study to investigate the efficacy and safety of ABBV-668 in subjects with moderate to severe UC. The study contains a 30-day screening period, 16-week treatment period, and a 30-day follow up period from the last dose of study …
Learn More

EFC17801

99 years and younger
All genders
The study will investigate the eficacy and safety of belumosudil compared with placebo, administered on top of azithromycin and SOC regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, at least 18 years age and with progressive CLAD despite azithromycin.
Learn More
541 - 550 of 930